Mestla

Apremilast, the active ingredient in Mestla, is a phosphodiesterase 4 (PDE4) inhibitor presented as an oral tablet for oral use. It is prescribed for adults with plaque psoriasis and psoriatic arthritis to reduce skin lesions and joint inflammation.

GNH USA supplies Mestla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Apremilast is indicated for inflammatory conditions that involve the phosphodiesterase‑4 pathway. - Plaque psoriasis: decreases the formation of red, scaly plaques on the skin, leading to clearer lesions and better quality of life for adult patients. - Psoriatic arthritis: lessens joint inflammation, pain and swelling, helping to preserve mobility and reduce disability in affected individuals.

Apremilast may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Headache: tension‑type head pain. - Upper respiratory tract infection: cold‑like symptoms. Serious or Rare Side Effects: - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Severe allergic reaction: rash, swelling, difficulty breathing. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating Mestla, several safety considerations should be reviewed. - Pregnancy: safety not established; avoid unless benefits outweigh potential risks. - Renal impairment: dose may need adjustment; monitor kidney function. - Hepatic impairment: use with caution; periodic liver‑function tests recommended. - Depression: monitor patients for mood changes or suicidal ideation. - Concomitant medications: review for potential interactions before prescribing. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Apremilast can interact with other medicines, requiring attention to the level of interaction. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase apremilast exposure and risk of side effects. - Strong CYP3A4 inducers (e.g., rifampin): may reduce apremilast effectiveness. - Live vaccines: increased risk of infection; avoid concurrent administration. Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for possible anticoagulant effect changes. - Diuretics: watch for electrolyte disturbances. - Alcohol: may exacerbate gastrointestinal upset.